BofA lowered the firm’s price target on Kura Oncology (KURA) to $27 from $29 and keeps a Buy rating on the shares. The firm says that while the company’s Q2 report didn’t bring new material insights, it remains encouraged about the story.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Kura Oncology’s Promising Future: Strong Financials and Advancements in AML Treatment Drive Buy Rating
- Kura Oncology Advances Cancer Drug Pipeline with FDA Review
- Kura Oncology: Strong Financials and Promising Clinical Developments Drive Buy Rating
- Kura Oncology’s Promising Clinical Developments and Financial Stability Justify Buy Rating
- Kura Oncology reports inducement grants under Nasdaq listing rule